Melanocortin Receptor-Binding Ligands

Anew Medical licensed rights to certain technology and know-how in the field of gamma-melanocortins comprised of drug and peptide chemicals, API and pharmaceuticals that bind, affect, and potentially treat diseases directly or indirectly related to human MC1R receptors.

On January 27, 2023, ANEW entered into a Sublicense Agreement with Teleost Biopharmaceuticals, LLC (“Teleost”) for the exclusive worldwide right to develop and commercialize certain patent rights owned by at least one of Intezyne; University Texas Board Regents; H Lee Moffitt; and University Arizona Board Regents, and licensed to Teleost, as well as an exclusive worldwide license to certain technology and know-how rights owned by Teleost in the field of gamma-melanocortins comprised of drug and peptide chemicals, API and pharmaceuticals that bind, affect, and potentially treat diseases directly or indirectly related to human MC1R receptors that do not compete or interfere withTeleost’s clinical cosmetic indications for use. The sublicensed patents arise from six families that claim compositions of matter and/or methods of use. The patents pertain to product candidates for treatment of dermal pathologies and for treatment of depression, PTSD, and cognition.